Art

J-GLOBAL ID：201702291429010633   Reference number：17A1130393

Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401)

ALK再配列陽性肺非小細胞癌患者に対するアレクチニブや一般状態不良(九州における肺腫瘍学グループ1401)【Powered by NICT】

Author (24)： Iwama Eiji (Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan) ,  Goto Yasushi (Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan) ,  Murakami Haruyasu (Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan) ,  Harada Taishi (Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan) ,  Tsumura Shinsuke (Department of Respiratory Medicine, Kumamoto Regional Medical Center, Kumamoto, Japan) ,  Sakashita Hiroyuki (Department of Clinical Oncology, Tokyo Medical and Dental University, Tokyo, Japan) ,  Sakashita Hiroyuki (Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan) ,  Mori Yoshiaki (Department of Respiratory Medicine, Iwate Prefectural Central Hospital, Morioka, Japan) ,  Nakagaki Noriaki (Department of Respiratory Medicine, Steel Memorial Yawata Hospital, Kita-Kyushu, Japan) ,  Fujita Yuka (Department of Respiratory Medicine, National Hospital Organization Asahikawa Medical Center, Asahikawa, Japan) ,  Seike Masahiro (Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan) ,  Bessho Akihiro (Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan) ,  Ono Manabu (Department of Respiratory Medicine, Kesen-numa City Hospital, Kesen-numa, Japan) ,  Okazaki Akihito (Division of Respiratory Medicine, Ishikawa Prefectural Central Hospital, Kanazawa, Japan) ,  Akamatsu Hiroaki (Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan) ,  Morinaga Ryotaro (Department of Thoracic Medical Oncology, Oita Prefectural Hospital, Oita, Japan) ,  Ushijima Shinichiro (Department of Respiratory Medicine, Fukuoka University Chikushi Hospital, Chikushino, Japan) ,  Shimose Takayuki (Clinical Research Support Center Kyushu, Fukuoka, Japan) ,  Tokunaga Shoji (Medical Information Center, Kyushu University Hospital, Fukuoka, Japan) ,  Hamada Akinobu (Division of Clinical Pharmacology and Translational Research, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tokyo, Japan) ,  Yamamoto Nobuyuki (Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan) ,  Nakanishi Yoichi (Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan) ,  Sugio Kenji (Department of Thoracic and Breast Surgery, Oita University, Oita, Japan) ,  Okamoto Isamu (Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan)
Material： Journal of Thoracic Oncology
Volume： 12  Issue： 7  Page： 1161-1166  Publication year： 2017 
JST Material Number： W3145A  ISSN： 1556-0864  Document type： Article
Article type： 原著論文  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Abstract/Point： Alectinib has shown marked eff...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A1130393&from=J-GLOBAL&jstjournalNo=W3145A") }}

Thesaurus term： oral administration ,  phase 2 study ,  gene ,  *non-small cell lung cancer ,  *patient ,  median value ,  therapy ,  Safety ,  toxicity ,  receptor tyrosine kinase ,  confidence interval ,  end point ,  adverse reaction ,  molecular targeting drug
Semi thesaurus term： 有害事象 ,  *再配列 , 【Automatic Indexing@JST】

Author keywords (5)： Alectinib ,  Poor performance status ,  ALK rearrangement ,  NSCLC ,  Pharmacokinetics

JST classification (2)： Clinical application of antitumor(=antineoplastic)drugs  (GW16020L) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Substance index (1)： Alectinib

Terms in the title (8)： ALK ,  再配列 ,  肺非小細胞癌 ,  患者 ,  アレクチニブ ,  九州 ,  肺腫瘍 ,  グループ